Biomarkers: Peripheral blood-based molecular signatures (Milestone 9.G)
Timeline Start - End2016 - 2020
Research Implementation AreaBiomarkers
Initiate studies to link peripheral blood-based molecular signatures and central imaging and CSF biomarkers.
Identification of 3 peripheral blood-based molecular signatures that have a high correlation with central imaging and/or CSF biomarkers.
Summary of Key Accomplishments
Research supported by the NIA led to the discovery and ongoing standardization/validation of plasma amyloid, tau and neurofilament light chain (NfL) biomarkers, reflecting accumulation of amyloid and tau in the brain and neurodegeneration. NIA supports a growing portfolio of projects focused on using genomic technologies (transcriptomic, proteomic, metabolomic) to discover blood-based and CSF-based biomarkers that can be used for diagnostic, prognostic purposes or as biomarkers of treatment response. These include projects that are using single-cell molecular profiling technologies.
Studies supported through the Accelerating Medicines Partnership for Alzheimer’s Disease (AMP AD) have identified multiple blood and CSF metabolite-based and protein-based signatures that correlate with CNS imaging biomarkers for AD for early and advanced stages of the disease.
The key accomplishments summary is current as of March 2022.
- PAR-15-359: Novel Approaches to Diagnosing Alzheimer's Disease & Predicting Progression (R01)
- PAR-17-054: Leveraging Existing Cohort Studies to Clarify Risk and Protective Factors for Alzheimer’s Disease and Related Dementias (R01)
- RFA-AG-15-010: Interdisciplinary Research to Understand the Vascular Contributions to Alzheimer's Disease (R01)
- RFA-AG-15-011: Biomarkers of Alzheimer’s Disease in Down Syndrome (R01)
- RFA-AG-18-013: Continuation of the AMP AD Target Discovery and Preclinical Validation Consortium
Research Programs and Resources
- Alzheimer’s Biomarkers Consortium – Down Syndrome (ABC-DS)
- Molecular Mechanisms of the Vascular Etiology of Alzheimer's Disease (M²OVE-AD) Consortium
- FNIH Biomarkers Consortium Launches a Project to Select Blood Tests that Detect Early Alzheimer's Disease